ARAC-the montreal jewish general hospital alzheimer risk assessment clinic

Canadian Journal of Neurological Sciences

Volumn 38, Issue 4, 2011, Pages 600-611

  Schipper, Hyman ^a   Liberman, Adrienne ^a   Kelner, Nora ^a   Babins, Lennie ^a   Fried, Lynda ^a   Bilbul, Melanie ^a   Goodman, Rachel ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; CANADA; FAMILY HISTORY; GENETIC RISK; HOSPITAL DEPARTMENT; HUMAN; MIDDLE AGED; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHORT TERM MEMORY; ADULT; AGED; GENERAL HOSPITAL; HOSPITAL; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; QUESTIONNAIRE; RISK ASSESSMENT;

ADULT; AGED; ALZHEIMER DISEASE; CANADA; HOSPITALS, GENERAL; HOSPITALS, PROPRIETARY; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 80053304748     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100012142     Document Type: Review

References (30)

1. Chertkow H, Bergman H, Schipper HM, et al. Assessment of suspected dementia. Can J Neurol Sci. 2001;28 Suppl 1:S28-41.
2. Schipper HM, Bilbul M. Risk profiles of Alzheimer disease. Can J Neurol Sci. 2011;38(4):580-92.
3. Hughes TF, Ganguli M. Modifiable midlife risk factors for late-life cognitive impairment and dementia. Curr Psychiatry Rev. 2009;5 (2):73-92.
4. Patterson C, Feightner JW, Garcia A, MacKnight C. General risk factors for dementia: A systematic evidence review. Alzheimer's Dement. 2007;3:341-7.
5. Patterson C, Feightner JW, Garcia A, MacKnight C. Primary prevention of dementia. Alzheimers Dement. 2007;3:348-54.
6. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Brit J Med. 2001;322(7300):1447-51.
7. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, populationbased study. Lancet Neurol. 2006;5(9):735-41.
8. Khachaturian ZS, Khachaturian AS. Prevent Alzheimer's disease by 2020: A national strategic goal. Alzheimer's Dement. 2009;5(2): 81-4.
9. Khachaturian ZS, Snyder PJ, Doody R, et al. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009;5(2):85-92.
10. Schipper HM.Apolipoprotein E: Implications forAD neurobiology, epidemiology and risk assessment. Neurobiol Aging.10 1016/j. neurobiolaging.2009.04.021.
11. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol. 2005;18(4):250-5.
12. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009; 361(3):245-54.
13. Roberts JS. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist. 2000;40(1):43-52.
14. Roberts JS, LaRusse SA, Katzen H, et al. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17(2):86-93.
15. Fanshawe TR, Prevost AT, Roberts JS, Green RC, Armstrong D, Marteau TM. Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test. 2008;12(3):381-6.
16. Schipper HM. Presymptomatic apolipoprotein E genotyping forAD risk assessment and prevention. Alzheimers Dement. [in press] 2011.
17. Finch CE. Toward a biology of middle age. In: Lachman ME, editor. Handbook of midlife development. New York: John Wiley & Sons. p. 77-108.
18. Lachman ME. Development in midlife. Annu Rev Psychol. 2004; 55:305-31.
19. Severson JA, Marcusson J, Winblad B, Finch CE. Age-correlated loss of dopaminergic binding sites in human basal ganglia. J Neurochem. 1982;39(6):1623-31.
20. Perneczky R, Wagenpfeil S, Lunetta KL, et al. Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. Neurology. 2010;75(2):137-42.
21. Borenstein Graves A, Mortimer JA, Bowen JD, et al. Head circumference and incidentAlzheimer's disease: modification by apolipoprotein E. Neurology. 2001;57(8):1453-60.
22. Schofield PW, Logroscino G, Andrews HF, Albert S, Stern Y. An association between head circumference andAlzheimer's disease in a population-based study of aging and dementia. Neurology. 1997;49(1):30-7.
23. Khachaturian ZS. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimer's Dement. 2009;5 (2):85-92.
24. la Fougere C, Grant S, Kostikov A, et al. Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. Neuroimage. [In press] 2010.
25. Feher A, Juhasz A, Rimanoczy A, Kalman J, Janka Z. Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis Assoc Disord. 2009;23(3):224-8.
26. Burns DH, Rosendahl S, Bandilla D, Maes OC, Chertkow HM, Schipper HM. Near-infrared spectroscopy of blood plasma for diagnosis of sporadic Alzheimer's disease. J Alzheimers Dis. 2009;17:391-7.
27. Schipper HM, Kwok CS, Rosendahl SM, et al. Spectroscopy of human plasma for diagnosis of idiopathic Parkinson disease. Biomarkers Med. 2008;2:229-38.
28. Kreindler S. Lifting the burden of chronic disease: What's worked, what hasn't, what next. Winnipeg Regional Health Authority. 2008
29. PESTLE Analysis. Renewal Associates, 2003.
30. Ahmed S, Gogovor A, Berman E, et al. Changing healthcare: stakeholder perceptions of the burden of chronic disease and the value of teams, measurements and communication. Healthc Q. 2009;12(2):e1-e13.